Hedgehog Pathway Inhibition by Novel Small Molecules Impairs Melanoma Cell Migration and Invasion under Hypoxia.

Hedgehog pathway carbonic anhydrases chemical compounds hypoxia

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
08 Feb 2024
Historique:
received: 09 01 2024
revised: 31 01 2024
accepted: 06 02 2024
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: epublish

Résumé

Melanoma is the principal cause of death in skin cancer due to its ability to invade and cause metastasis. Hypoxia, which characterises the tumour microenvironment (TME), plays an important role in melanoma development, as cancer cells can adapt and acquire a more aggressive phenotype. Carbonic anhydrases (CA) activity, involved in pH regulation, is related to melanoma cell migration and invasion. Furthermore, the Hedgehog (Hh) pathway, already known for its role in physiological processes, is a pivotal character in cancer cell growth and can represent a promising pharmacological target. In this study, we targeted Hh pathway components with cyclopamine, glabrescione B and C22 in order to observe their effect on carbonic anhydrase XII (CAXII) expression especially under hypoxia. We then performed a migration and invasion assay on two melanoma cell lines (SK-MEL-28 and A375) where Smoothened, the upstream protein involved in Hh regulation, and GLI1, the main transcription factor that determines Hh pathway activation, were chemically inhibited. Data suggest the existence of a relationship between CAXII, hypoxia and the Hedgehog pathway demonstrating that the chemical inhibition of the Hh pathway and CAXII reduction resulted in melanoma migration and invasion impairment especially under hypoxia. As in recent years drug resistance to small molecules has arisen, the development of new chemical compounds is crucial. The multitarget Hh inhibitor C22 proved to be effective without signs of cytotoxicity and, for this reason, it can represent a promising compound for future studies, with the aim to reach a better melanoma disease management.

Identifiants

pubmed: 38399442
pii: ph17020227
doi: 10.3390/ph17020227
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : MIUR
ID : 393 2017NTK4HY_002
Organisme : Ministry of Education, Universities and Research
ID : B63C22000680007

Auteurs

Alessandro Falsini (A)

Cellular and Molecular Physiology Unit, Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.

Gaia Giuntini (G)

Cellular and Molecular Physiology Unit, Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.

Mattia Mori (M)

Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.

Francesca Ghirga (F)

Department of Chemistry and Technology of Drugs, Sapienza University of Rome, 00185 Rome, Italy.

Deborah Quaglio (D)

Department of Chemistry and Technology of Drugs, Sapienza University of Rome, 00185 Rome, Italy.

Antonino Cucinotta (A)

Department of Molecular Medicine, Sapienza University, 00161 Rome, Italy.

Federica Coppola (F)

Cellular and Molecular Physiology Unit, Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.

Irene Filippi (I)

Cellular and Molecular Physiology Unit, Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.

Antonella Naldini (A)

Cellular and Molecular Physiology Unit, Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.

Bruno Botta (B)

Department of Chemistry and Technology of Drugs, Sapienza University of Rome, 00185 Rome, Italy.

Fabio Carraro (F)

Cellular and Molecular Physiology Unit, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Classifications MeSH